ReviewInternational journal of oncology2020
Update on uveal melanoma: Translational research from biology to clinical practice (Review).
Review in International journal of oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- A Possible Link Between Cutaneous Melanoma and Uveal Melanoma: A Multicenter Retrospective Cohort Study.Cancers · 2026Article
- Article
- Network-based analysis reveals potential microRNA regulation of oncogenic pathways in SOX10-depleted uveal melanoma.Cellular and molecular life sciences : CMLS · 2026Article
- Article
- Associations of Social and Demographic Factors on the Outcomes of Ocular Melanoma and Other Adult Ocular Neoplasms in the United States: A Systematic Review.Cochrane evidence synthesis and methods · 2026Review
- Review
- Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma.Cancer reports (Hoboken, N.J.) · 2025Review
- Intensive Surveillance and Aggressive Multimodal Treatment for Liver Metastases From Uveal Melanoma.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2025Article
- Article
- Current Treatment of Uveal Melanoma.Cancers · 2025Review
- Factors associated with time until metastatic spread in patients with primary uveal melanoma: A retrospective analysis.PloS one · 2025Article
- Global research trends in metabolism-related intraocular malignancies: a multi-database bibliometric analysis and cross-validation study.Frontiers in molecular biosciences · 2025Article
- Significance of Aneuploidy in Predicting Prognosis and Treatment Response of Uveal Melanoma.Current medicinal chemistry · 2025Article
- Development of a prognostic risk model of uveal melanoma based on N7-methylguanosine-related regulators.Hereditas · 2024Article
- Article
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- Pathological and Molecular Diagnosis of Uveal Melanoma.Diagnostics (Basel, Switzerland) · 2024Review
- Assessment of Social Vulnerabilities of Care and Prognosis in Adult Ocular Melanomas in the US.Annals of surgical oncology · 2024Article
- FOXM1 promote the growth and metastasis of uveal melanoma cells by regulating CDK2 expression.International ophthalmology · 2024Article
- Cuproptosis and its application in different cancers: an overview.Molecular and cellular biochemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma is the most common type of intraocular cancer with a low mean annual incidence of 5‑10 cases per million. Tumours are located in the choroid (90%), ciliary body (6%) or iris (4%) and of 85% are primary tumours. As in cutaneous melanoma, tumours arise in melanocytes; however, the characteristics of uveal melanoma differ, accounting for 3‑5% of melanocytic cancers. Among the numerous risk factors are age, sex, genetic and phenotypic predisposition, the work environment and dermatological conditions. Management is usually multidisciplinary, including several specialists such as ophthalmologists, oncologists and maxillofacial surgeons, who participate in the diagnosis, treatment and complex follow‑up of these patients, without excluding the management of the immense emotional burden. Clinically, uveal melanoma generates symptoms that depend as much on the affected ocular globe site as on the tumour size. The anatomopathological study of uveal melanoma has recently benefited from developments in molecular biology. In effect, disease classification or staging according to molecular profile is proving useful for the assessment of this type of tumour. Further, the improved knowledge of tumour biology is giving rise to a more targeted approach to diagnosis, prognosis and treatment development; for example, epigenetics driven by microRNAs as a target for disease control. In the present study, the main epidemiological, clinical, physiopathological and molecular features of this disease are reviewed, and the associations among all these factors are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.